BLAINJECTIONINJECTABLE
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
HULIO (adalimumab-fkjp) by Viatris (2) is tnf-alpha and block its interaction with the p55 and p75 cell surface tnf receptors. Approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and 4 more indications. First approved in 2020.
Drug data last refreshed 18h ago
Mechanism of Action
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is…
Indications (7)
Worked on HULIO at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.